Information Provided By:
Fly News Breaks for April 5, 2016
BSX
Apr 5, 2016 | 07:49 EDT
After attending Boston Scientific's investor meeting, RBC Capital believes that the launches of the company's Synergy and Watchman devices are ahead of plan. As a result, the firm thinks that the company's 2016 results should come in above consensus estimates. RBC keeps a $20 price target and Outperform rating on the shares.